EHA 2023 | Key observations from the APL Asian Consortium: improved patient outcomes with AAA-based regimens

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, discusses a multicenter cohort analysis of the APL Asian Consortium (APLAC; NCT04251754), investigating different regimens used in the frontline induction and maintenance of first complete remission in patients with newly diagnosed acute promyelocytic leukemia (APL). The analysis compared the regimen of oral arsenic trioxide (ATO), all-trans retinoic acid (ATRA) and ascorbic acid (AAA-based regimen) to intravenous (i.v.) ATO/ATRA-based and ATRA/chemotherapy-based regimens. Key observations include both the AAA-based and i.v.-ATO/ATRA-based regimens improving 60-day survival, and the superiority of the AAA-based regimen in improving overall survival (OS), relapse-free survival (RFS) and post-60-day survival compared to the i.v.-ATO/ATRA-based and ATRA/chemotherapy-based regimens. This study highlights the effectiveness of oral AAA-based regimes in patients with APL compared to less affordable intravenous regimens. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.